Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Google DeepMind is getting ready to begin human testing of drugs developed using artificial intelligence. All you need to know ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Clinical trials remain the cornerstone of evidence-based medicine, yet they are frequently protracted and costly. More often ...

Isomorphic Labs, a DeepMind spinoff, is close to starting human trials for AI-designed drugs. The company aims to speed up drug discovery, reduce costs, and improve success rates in medicine.

Industry experts see this breakthrough as a potential game-changer in biomedical research and development. Google DeepMind spinoff Biotech moves AI-designed drug to human trials 中文網 ...

A New Era of Research with Health Studio Clinical trials are the backbone of medical advancement but they’ve historically ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting everything on AI to beat the odds.